These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Factors associated with spontaneous release of vitreomacular traction. Almeida DR; Chin EK; Rahim K; Folk JC; Russell SR Retina; 2015 Mar; 35(3):492-7. PubMed ID: 25207947 [TBL] [Abstract][Full Text] [Related]
6. Vitreous in Age-Related Macular Degeneration Therapy--The Medium Is the Message. Sebag J Retina; 2015 Sep; 35(9):1715-8. PubMed ID: 26312447 [No Abstract] [Full Text] [Related]
7. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy. Cho HJ; Baek JS; Lee DW; Cho SW; Kim CG; Kim JW Retina; 2013; 33(10):2126-32. PubMed ID: 23609123 [TBL] [Abstract][Full Text] [Related]
8. Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. Kanadani TCM; Dos Reis Veloso CE; Dorairaj S; Nehemy MB Ophthalmic Res; 2017; 58(1):18-26. PubMed ID: 28301850 [TBL] [Abstract][Full Text] [Related]
9. Vitreomacular adhesion or vitreomacular traction may affect antivascular endothelium growth factor treatment for neovascular age-related macular degeneration. Xie P; Zheng X; Yu Y; Ye X; Hu Z; Yuan D; Liu Q Br J Ophthalmol; 2017 Aug; 101(8):1003-1010. PubMed ID: 28596285 [TBL] [Abstract][Full Text] [Related]
10. Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ciulla TA; Ying GS; Maguire MG; Martin DF; Jaffe GJ; Grunwald JE; Daniel E; Toth CA; Ophthalmology; 2015 Jun; 122(6):1203-11. PubMed ID: 25824327 [TBL] [Abstract][Full Text] [Related]
11. INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED MACULAR DEGENERATION (VINTREX). Houston SK; Rayess N; Cohen MN; Ho AC; Regillo CD Retina; 2015 Sep; 35(9):1757-64. PubMed ID: 26110596 [TBL] [Abstract][Full Text] [Related]
12. Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy? Bopp S Br J Ophthalmol; 2007 Oct; 91(10):1259-60. PubMed ID: 17895411 [TBL] [Abstract][Full Text] [Related]
13. Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis? la Cour M Acta Ophthalmol Scand; 2007 Feb; 85(1):2-4. PubMed ID: 17244202 [No Abstract] [Full Text] [Related]
14. Anti-VEGF therapy in symptomatic peripheral exudative hemorrhagic chorioretinopathy (PEHCR) involving the macula. Seibel I; Hager A; Duncker T; Riechardt AI; Nürnberg D; Klein JP; Rehak M; Joussen AM Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):653-9. PubMed ID: 26148802 [TBL] [Abstract][Full Text] [Related]
15. Comparing ranibizumab with bevacizumab. Biswas P; Sengupta S; Choudhary R; Home S; Paul A; Sinha S Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243 [No Abstract] [Full Text] [Related]
16. The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice. Hussain N; Ghanekar Y; Kaur I Indian J Ophthalmol; 2007; 55(6):445-50. PubMed ID: 17951902 [TBL] [Abstract][Full Text] [Related]
17. Vitreomacular traction in a case of exudative age-related macular degeneration resistant to anti-VEGF therapy. Shah SU; Haller JA Acta Ophthalmol; 2012 Nov; 90(7):e569-70. PubMed ID: 22429537 [No Abstract] [Full Text] [Related]
18. Tachyphylaxis and bevacizumab. Avgikos KN; Horgan SE; Sivaraj RR; Hu K Ophthalmology; 2009 Sep; 116(9):1831-2; author reply 1832. PubMed ID: 19729101 [No Abstract] [Full Text] [Related]